You can buy or sell VBLT and other stocks, options, ETFs, and crypto commission-free!
Vascular Biogenics Ltd. Ordinary Shares, also called Vascular Biogenics, is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. Read More It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
52 Week High
52 Week Low
Yahoo FinanceMay 8
Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know
Vascular Biogenics (VBLT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
Yahoo FinanceMay 6
VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15
TEL AVIV, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Wednesday, May 15 at 8:30am Eastern Time to report first quarter ended March 31, 2019 financial results and to provide a corporate update.
-$0.12 per share
-$0.12 per share